You just read:

Novartis announces NEJM publication of two phase III studies demonstrating high efficacy of investigational new drug secukinumab (AIN457) in psoriasis patients

News provided by

Novartis Pharmaceuticals Canada Inc.

Aug 05, 2014, 09:18 ET